Search

Your search keyword '"Burstein H"' showing total 7 results
Start Over Author "Burstein H" Language undetermined
7 results on '"Burstein H"'

1. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Author

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A, and SOLE Investigators

Published
2018

2. Breast cancer: Clinical practice guidelines in oncology

Author

Carlson, R. W., Anderson, B. O., Burstein, H. J., Cox, C. E., Edge, S. B., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C., Jahanzeb, M., Ljung, B. M., Marks, L. B., Beryl Mc Cormick, Nabell, L. M., Pierce, L. J., Reed, E. C., Silver, S. M., Smith, M. L., Somlo, G., Theriault, R. L., Ward, J. H., Winer, E. P., and Wolff, A. C.

4. NCCN task force report: mTOR inhibition in solid tumors

Author

Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson Iii, A. B., Burstein, H. J., Ettinger, D. S., Febbo, P. G., Fury, M. G., Hudes, G. R., Kies, M. S., Kwak, E. L., Morgan Jr, R. J., Joanne Mortimer, Reckamp, K., Venook, A. P., Worden, F., and Yen, Y.

5. Invasive breast cancer: Clinical practice guidelines in oncology

Author

Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C. A., Ljung, B. -M, Mankoff, D. A., Marcom, P. K., Mayer, I. A., Mccormick, B., Pierce, L. J., Reed, E. C., Sachdev, J., Smith, M. L., Somlo, G., Ward, J. H., Antonio Wolff, and Zellars, R.

6. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?

Author

Umberto Veronesi, Mehra Golshan, Giuseppe Viale, Angela Esposito, Mario Giuliano, Harold J. Burstein, Giuseppe Curigliano, Stephanie M. Wong, Michele Santangelo, Carmen Criscitiello, Criscitiello, C, Curigliano, G, Burstein, H. J, Wong, S, Esposito, A, Viale, G, Giuliano, Mario, Veronesi, U, Santangelo, Michele, and Golshan, M.

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, Clinical Decision-Making, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Medical Overuse, Mastectomy, Segmental, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Breast conserving surgery, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Breast-conserving surgery, Humans, Genetic Predisposition to Disease, In patient, 030212 general & internal medicine, Intensive care medicine, Mastectomy, Neoadjuvant therapy, Breast conservation, Surgical approach, business.industry, Cancer, Patient Preference, General Medicine, medicine.disease, Neoadjuvant Therapy, Surgical Oncology, 030220 oncology & carcinogenesis, Axilla, Hereditary Breast and Ovarian Cancer Syndrome, Lymph Node Excision, Female, Surgery, business
Abstract

The main rationale for neoadjuvant therapy for breast cancer is to provide effective systemic treatment while surgically down-staging the cancer. This down-staging was initially to convert inoperable patients to operable and later to increase rates of breast conservation in patients initially deemed mastectomy only candidates. Unexpectedly, in recent neoadjuvant trials lower rates of breast conservation have been observed than in past decades, despite remarkable advances in systemic therapies, which have increased pathologic complete response rates. These results point to factors aside from response and eligibility for breast conservation that may lead surgeons and/or patients to recommend and choose mastectomy. Here, we aim to examine the surgical benefits offered by the modern era neoadjuvant therapy and explore factors that have contributed to this decrease in breast conservation rates. If the main benefit of neoadjuvant therapy is to increase the opportunity for breast conservation, then our review suggests that to optimize less invasive surgical approaches, we will need to address both surgeon and patient-level variables and biases that may be limiting our ability to identify patients appropriate for less aggressive options. As an oncology community, we must be aware of the surgical overtreatment of breast cancer, especially in a time where systemic therapies have remarkably improved outcomes and responses.

Published
2016

7. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Author

Bahadir M. Gulluoglu, A. Di Leo, Jonas Bergh, Jens Huober, Kent Osborne, Bo Xu, Beat Thürlimann, Chiun-Sheng Huang, Masakazu Toi, Eric P. Winer, Pamela J. Goodwin, Toshihiro Watanabe, Roberto Orecchia, Andrew Tutt, Ann H. Partridge, Nadia Harbeck, Felix Sedlmayer, Sara Y. Brucker, H.-J. Senn, José Baselga, Michael Gnant, Timothy J. Whelan, Jack Cuzick, Zefei Jiang, Zhimin Shao, Bent Ejlertsen, Emiel J. Th. Rutgers, Sibylle Loibl, Daniel F. Hayes, Meredith M. Regan, Jungsil Ro, Olivia Pagani, Prudence A. Francis, Vladimir Semiglazov, Judy Garber, Carsten Denkert, H. Khaled, Lisa A. Carey, Viviana Galimberti, Giuseppe Curigliano, Giuseppe Viale, I.E. Smith, Marco Colleoni, Monica Morrow, Harold J. Burstein, Eva Ciruelos, Hervé Bonnefoi, Per Karlsson, Fabrice Andre, Jacek Jassem, Martine Piccart-Gebhart, Peter Dubsky, Fatima Cardoso, Kathleen I. Pritchard, Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H. -J., Thurlimann, B., Andre, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S. Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D. F., Huang, C. -S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K. C., Pagani, O., Partridge, A. H., Pritchard, K., Ro, J., Rutgers, E. J. T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T. J., and Xu, B.

Subjects
0301 basic medicine, Oncology, medicine.medical_treatment, Systemic therapy, radiation therapy, Primary therapy, surgery, NEOADJUVANT CHEMOTHERAPY, DOUBLE-BLIND, 0302 clinical medicine, Stage (cooking), Neoadjuvant therapy, Early breast cancer, DISTANT RECURRENCE, Hematology, CONSERVING SURGERY, Corrigenda, Chemotherapy regimen, Combined Modality Therapy, Neoadjuvant Therapy, LYMPH-NODE BIOPSY, POSTMENOPAUSAL WOMEN, CARCINOMA IN-SITU, 030220 oncology & carcinogenesis, Austria, Surgical Procedures, Operative, Special Articles, Female, medicine.medical_specialty, Antineoplastic Agents, Breast Neoplasms, systemic adjuvant therapies, 03 medical and health sciences, Breast cancer, Adjuvants, Immunologic, Internal medicine, St Gallen Consensus, Adjuvant therapy, medicine, Humans, early breast cancer, ENDOCRINE THERAPY, Radiotherapy, business.industry, Carcinoma in situ, Cancer, Expert consensus, medicine.disease, Radiation therapy, 030104 developmental biology, Annals, Early Diagnosis, AXILLARY DISSECTION, 21-GENE RECURRENCE SCORE, business
Abstract

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results